Skip to content
DataLookout
Menu

NCT07767448

Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 10 words Show 4 more changesShow less
    • Start date pushed from Oct 2026 to Nov 2026
    • Interventions modified
    • Secondary endpoints: details revised at 3 of 3 entries
    • Collaborators: details revised at 1 of 1 entry
  2. Notable Start date: Aug 2026 to Oct 2026
    • Study title shortened, about 2 words
    v3
  3. Minor Study title shortened, about 4 wordsv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in Patient-Reported Skin Dryness Severity
Timeframe: From baseline visit to follow-up visit (approximately 2-4 weeks).

Secondary (3)

Time to improvement in dryness symptoms
Change in Stratum Corneum Hydration
Change in Transepidermal Water Loss (TEWL)

Arms and interventions

MoisturizerExperimental

Participants in this arm will apply the following cosmeceutical topical moisturizers twice daily (once in the morning and once in the evening) for the duration of the study: 1. CeraVe Moisturizing Cream (once in the morning and once in the evening) 2. La Roche Posay Lipikar AP+ triple repair moisturizing cream (once in the morning and once in the evening) 3. La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+) (once in the morning and once in the evening)

Other: CeraVe Moisturizing Cream, La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream, La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)

Sites

1 site in 1 country

  • Stanford Health Care: Supportive Dermato-Oncology ProgramPalo Alto, California, United States